The use of beta-blockers in patients with chronic obstructive pulmonary disease and chronic heart failure in real clinical practice
https://doi.org/10.21886/2712-8156-2021-2-1-70-75
Abstract
Objective: to reveal the features of the use of beta-blockers (BB) in patients with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) in real clinical practice.
Materials and methods: the study included 90 patients with COPD and CHF, and 41 patients with CHF of ischemic genesis without COPD.
Results: patients with COPD and CHF were significantly less likely to receive beta-blockers (BB) compared with patients with CHF. Of the BB patients with COPD and CHF were primarily prescribed bisoprolol, its average dose was 4.45 ± 1.74 mg per day. Patients with COPD and CHF of ischemic genesis of BB were prescribed significantly more often, and diuretics were significantly less likely than patients with COPD and CHF without myocardial infarction. Patients with COPD and CHF with ejection fraction of the left ventricle (LVEF) more than 40% were less likely to take BB than patients with COPD and CHF with reduced EF (less than 40%), and also less frequently, than patients with CHF without COPD with LVEF more than 40%.
Conclusion: BB, as first-line drugs in the treatment of CHF, was prescribed on an outpatient basis only to half of patients with COPD and CHF, which does not comply with current guidelines for the management of patients with comorbid conditions. In the vast majority of cases, highly selective BB were prescribed. It should be noted low doses of BB, the absence of dose titration, which does not correspond to modern recommendations for the treatment of chronic heart failure.
About the Authors
N. A. Karoli
V.I. Razumovsky Saratov State Medical University
Russian Federation
Russian Federation
Nina A. Karoli, Dr. Sci. (Med.), professor of hospital therapy chair of general medicine Department.
Saratov
A. V. Borodkin
Tambov central district hospital
Russian Federation
Russian Federation
Andrey V. Borodkin, Cand Sci. (Med.), cardiologist.
Tambov
A. P. Rebrov
V.I. Razumovsky Saratov State Medical University
Russian Federation
Russian Federation
Andrey P. Rebrov, Dr. Sci. (Med.), professor, head of the chair of hospital therapy of general medicine Department.
Saratov
References
1. Corrao S, Brunori G, Lupo U, Perticone F. Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities. Eur Respir Rev. 2017;26(145):160123. DOI: 10.1183/16000617.0123-2016
2. Recio Iglesias J, Diez-Manglano J, Lopez Garcia F, Diaz Peromingo JA, Almagro P, Varela Aguilar JM. Management of the COPD Patient with Comorbidities: An Experts Recommendation Document. Int J Chron Obstruct Pulmon Dis. 2020;15:1015-1037. DOI: 10.2147/COPD.S242009
3. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39(1):51-8. DOI: 10.1183/09031936.00044411
4. Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, et al. The cardiopulmonary continuum systemic inflammation as 'common soil' of heart and lung disease. Int J Cardiol. 2010;145(2):172-176. DOI: 10.1016/j.ijcard.2010.04.082
5. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал сердечная недостаточность. 2013;14(7):379-472. eLIBRARY ID: 25276123
6. Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD 2019). 2019
7. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А., и др. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI: 10.18087/cardio.2475
8. Малявин А.Г., Мартынов А.И., Адашева Т.В. и др. Национальные клинические рекомендации. Диагностика и лечение пациентов с хронической обструктивной болезнью легких и хронической сердечной недостаточностью. Терапия. 2019;5(S):59-104.
9. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566. DOI: 10.1002/14651858.CD003566.pub2
10. Ni Y, Shi G, Wan H. Use of cardioselective в-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40(6):2051-65. DOI: 10.1177/030006051204000602.
11. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between в-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67(11):977-84. DOI: 10.1136/thoraxjnl-2012-201945.
12. Huang YL, Lai CC, Wang YH, Wang CY, Wang JY, Wang HC, et al. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2987-2996. DOI: 10.2147/COPD.S145913.
13. Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J, et al. Underuse of в-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909-1914. DOI: 10.1136/heartjnl-2016-309458.
14. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292-8. DOI: 10.1093/eurjhf/hfp001.
15. Neef PA, McDonald CF, Burrell LM, Irving LB, Johnson DF, Steinfort DP. Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and comorbid cardiac disease. Intern Med J. 2016;46(11):1336-1340. DOI: 10.1111/imj.13240
16. Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3041-3046. DOI: 10.2147/COPD.S144333.
17. Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano A, et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2020;6(1):23-31. DOI: 10.1093/ehjqcco/qcy063.
18. Лукьянов М.М., Козминский А.Н., Марцевич С.Ю., Якушин С.С., Воробьев А.Н., Загребельный А.В., и др. Больные с сочетанием хронической сердечной недостаточности, артериальной гипертонии и перенесенного ранее инфаркта миокарда: клинико-анамнестические характеристики и практика назначения ингибиторов ангиотензин-превращающего фермента, блокаторов рецепторов ангиотензина и В-адреноблокаторов, приверженность лечению (данные амбулаторного регистра Рекваза). Рациональная Фармакотерапия в Кардиологии. 2017;13(2):207-212. DOI: 10.20996/1819-6446-2017-13-2-207-212
19. Марцевич С.Ю., Захарова Н.А., Кутишенко Н.П., Загребельный А.В., Лукина Ю.В., Лукьянов М.М., и др. Практика применения бета-адреноблокаторов у больных с сердечнососудистыми заболеваниями при хронических болезнях органов дыхания. Данные амбулаторных регистров Профиль и Рекваза. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):469-475. DOI: 10.20996/1819-6446-2017-13-4-469-475
20. Кароли Н.А., Бородкин А.В., Ребров А.П. Хроническая сердечная недостаточность различного генеза у больных хронической обструктивной болезнью легких. Пульмонология. 2016;26(1):38-45. DOI: 10.18093/0869-0189-2016-26-1-38-45
Review
For citations:
Karoli N.A., Borodkin A.V., Rebrov A.P. The use of beta-blockers in patients with chronic obstructive pulmonary disease and chronic heart failure in real clinical practice. South Russian Journal of Therapeutic Practice. 2021;2(1):70-75. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-1-70-75
Views:
5088
Email this article 